High Triglyceridemia-Pipeline Review, H1 2015

High Triglyceridemia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6045IDB
  • |
  • Pages: 105
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

High Triglyceridemia-Pipeline Review, H1 2015


Global Markets Direct's, 'High Triglyceridemia-Pipeline Review, H1 2015', provides an overview of the High Triglyceridemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of High Triglyceridemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for High Triglyceridemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the High Triglyceridemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

High Triglyceridemia Overview 9

Therapeutics Development 10

Pipeline Products for High Triglyceridemia-Overview 10

Pipeline Products for High Triglyceridemia-Comparative Analysis 11

High Triglyceridemia-Therapeutics under Development by Companies 12

High Triglyceridemia-Therapeutics under Investigation by Universities/Institutes 15

High Triglyceridemia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

High Triglyceridemia-Products under Development by Companies 19

High Triglyceridemia-Products under Investigation by Universities/Institutes 21

High Triglyceridemia-Companies Involved in Therapeutics Development 22

Acasti Pharma Inc. 22

Actavis plc 23

Alnylam Pharmaceuticals, Inc. 24

Arisaph Pharmaceuticals, Inc. 25

Astellas Pharma Inc. 26

AstraZeneca PLC 27


Cardax Pharmaceuticals, Inc. 29

Catabasis Pharmaceuticals, Inc. 30

Essentialis, Inc. 31

Isis Pharmaceuticals, Inc. 32

Jeil Pharmaceutical Co., Ltd. 33

Novartis AG 34

Pharmena SA 35

Poxel SA 36

Tekmira Pharmaceuticals Corp. 37

Thetis Pharmaceuticals LLC 38

High Triglyceridemia-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

ALN-AC3-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ALN-ANG-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ARI-3037MO-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AS-1708727-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

bezafibrate ER-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

BioE-1115-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CAT-2003-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CDX-085-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

diazoxide choline CR-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

ISIS-APOCIIIRx-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

MAT-9001-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

NKPL-66-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

pradigastat sodium-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

PRC-4016-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecule for Hypertriglyceridaemia-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecule to Agonize Farnesoid X Receptor for Metabolic Disorders, Cardiovascular and Gastrointestinal Disorders-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Small Molecules for Dyslipidemia and Hypertriglyceridemia-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Synthetic Peptides for Dyslipidemic and Vascular Disorders-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

TKM-HTG-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

TP-101-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

TP-110-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

TP-252-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

TP-8252-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

TRIA-662-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

High Triglyceridemia-Recent Pipeline Updates 80

High Triglyceridemia-Dormant Projects 94

High Triglyceridemia-Discontinued Products 95

High Triglyceridemia-Product Development Milestones 96

Featured News & Press Releases 96

Dec 23, 2014: Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission 96

Nov 12, 2014: Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001 97

Nov 10, 2014: Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001 97

Oct 29, 2014: Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001 98

Oct 20, 2014: Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia 99

Sep 30, 2014: Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014 99

Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 100

Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 101

Sep 04, 2014: Matinas BioPharma to Present at Three Investor Conferences in September 102

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 103

Appendix 104

Methodology 104

Coverage 104

Secondary Research 104

Primary Research 104

Expert Panel Validation 104

Contact Us 105

Disclaimer 105

List of Tables

Number of Products under Development for High Triglyceridemia, H1 2015 10

Number of Products under Development for High Triglyceridemia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

High Triglyceridemia-Pipeline by Acasti Pharma Inc., H1 2015 22

High Triglyceridemia-Pipeline by Actavis plc, H1 2015 23

High Triglyceridemia-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 24

High Triglyceridemia-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 25

High Triglyceridemia-Pipeline by Astellas Pharma Inc., H1 2015 26

High Triglyceridemia-Pipeline by AstraZeneca PLC, H1 2015 27

High Triglyceridemia-Pipeline by BASF SE, H1 2015 28

High Triglyceridemia-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 29

High Triglyceridemia-Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 30

High Triglyceridemia-Pipeline by Essentialis, Inc., H1 2015 31

High Triglyceridemia-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 32

High Triglyceridemia-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 33

High Triglyceridemia-Pipeline by Novartis AG, H1 2015 34

High Triglyceridemia-Pipeline by Pharmena SA, H1 2015 35

High Triglyceridemia-Pipeline by Poxel SA, H1 2015 36

High Triglyceridemia-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 37

High Triglyceridemia-Pipeline by Thetis Pharmaceuticals LLC, H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 43

Number of Products by Stage and Route of Administration, H1 2015 45

Number of Products by Stage and Molecule Type, H1 2015 47

High Triglyceridemia Therapeutics-Recent Pipeline Updates, H1 2015 80

High Triglyceridemia-Dormant Projects, H1 2015 94

High Triglyceridemia-Discontinued Products, H1 2015 95

List of Figures

Number of Products under Development for High Triglyceridemia, H1 2015 10

Number of Products under Development for High Triglyceridemia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Top 10 Targets, H1 2015 40

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Top 10 Routes of Administration, H1 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45

Number of Products by Top 10 Molecule Types, H1 2015 46

Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Acasti Pharma Inc.

Actavis plc

Alnylam Pharmaceuticals, Inc.

Arisaph Pharmaceuticals, Inc.

Astellas Pharma Inc.

AstraZeneca PLC


Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Essentialis, Inc.

Isis Pharmaceuticals, Inc.

Jeil Pharmaceutical Co., Ltd.

Novartis AG

Pharmena SA

Poxel SA

Tekmira Pharmaceuticals Corp.

Thetis Pharmaceuticals LLC

High Triglyceridemia Therapeutic Products under Development, Key Players in High Triglyceridemia Therapeutics, High Triglyceridemia Pipeline Overview, High Triglyceridemia Pipeline, High Triglyceridemia Pipeline Assessment

select a license

Single User License
USD 2000 INR 132420
Site License
USD 4000 INR 264840
Corporate User License
USD 6000 INR 397260



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com